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The current medical solution industry, with amazing scientists and 
businesspeople working as hard as they can, is not creating treatments and cures 
for most of the world’s diseases.  Pharma in 2013 is using a fifty-year-old 
business model to leverage current knowledge and technology, but that is 
generating few new treatments, and each treatment increases healthcare costs.  
We have created an incentive system that focuses treatment development on 
patients that can be treated with expensive consumables for long periods of 
time.  That system leaves most patients without hope of getting a for-profit 
medical solution.  We have to do something different if we expect to create 
more treatments and cures and lower healthcare costs. 
There are two ideas that could be merged to create a new incentive system.  
The first idea is to focus on finding new uses for the thousands of drugs and 
nutraceuticals already available for human use.  This is far cheaper, safer and 
faster than trying to create a new chemical entity.  There are lots of these 
Rediscovery Research™ opportunities but no simple way to share them, work 
on them together, or get them funded.  The second idea is to fund this clinical 
research from the healthcare cost savings it could create.  Payer systems track 
diseases and drugs by code, so it is possible to track the costs savings generated 
by a patient taking an approved “new” repurposed treatment to alleviate 
symptoms.  The government and other payers can create a payment pool, 
through a Social Impact Bond or some other vehicle, to pay for the dual 
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outcome of making patients healthier and reducing healthcare costs.  If that pool 
were large enough, it would create a strong incentive for for-profit companies 
and other investors to undertake or underwrite this repurposing research, and a 
way for non-profits and academics to participate.  The healthcare savings could 
be enormous, even for a very small patient population, allowing a focus on 
diseases that would otherwise be unprofitable. 
It is a big challenge, but it is impossible to tackle an enormous problem like 
disease without a disruptive change, and this disruptive change is simple 
enough to understand and to implement, and we have already shown it can 
work.  We must explore creative solutions to these healthcare challenges, via 
discussions at the interface of law, medicine, science, and public policy.  The 
articles and comments in this issue of the Marquette IPLR are a step towards 
furthering that dialog. 
 
 
  
